Key Points
- Director Blake Borgeson sold 30,000 shares on April 7 at an average price of $3.10 for a total of $93,000; the transaction was executed under a pre‑arranged Rule 10b5‑1 plan and left him with 6,229,863 shares (a 0.48% reduction).
- Borgeson also sold 220,000 shares on Feb 3 at $4.20 for about $924,000, signaling multiple recent insider disposals.
- Recursion posted Q4 EPS of -$0.21 (vs. -$0.28 estimate) and revenue of $35.54M (vs. $24.56M estimate) but remains unprofitable with a heavily negative net margin and ROE; the stock has a consensus "Hold" rating and a $9.40 price target, trading in a 52‑week range of $2.80–$7.18.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00. Following the sale, the director directly owned 6,229,863 shares of the company's stock, valued at $19,312,575.30. This represents a 0.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, February 3rd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX stock opened at $3.39 on Thursday. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -2.29 and a beta of 1.02. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.80 and a 52 week high of $7.18. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $3.50 and a 200-day moving average of $4.38.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company had revenue of $35.54 million during the quarter, compared to the consensus estimate of $24.56 million. During the same quarter last year, the firm posted ($0.53) EPS. The company's quarterly revenue was up 671.7% on a year-over-year basis. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $31,000. Sequoia Financial Advisors LLC bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $41,000. Allworth Financial LP raised its stake in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company's stock valued at $47,000 after acquiring an additional 4,403 shares during the period. IFP Advisors Inc raised its stake in Recursion Pharmaceuticals by 81.5% in the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company's stock valued at $51,000 after acquiring an additional 4,650 shares during the period. Finally, PFG Investments LLC bought a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $53,000. 89.06% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have weighed in on RXRX shares. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Finally, Wall Street Zen cut Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $9.40.
View Our Latest Research Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
